Category: Intellectual property
-
Companies Partner on Implanted Diabetes Beta Cell Device
A company developing implants that release cell therapies is collaborating with a producer of regenerative stem cells to dispense insulin for people with diabetes.
-
Univ. Lab Licenses Protein for Vaccine Patch
A company developing a needle patch for vaccine delivery is acquiring the rights to a synthetic SARS-Cov-2 spike protein for its Covid-19 vaccine patch.
-
Drug Discovery Biotech Inks Partnering Deal, Gains $175M
A biotechnology company discovering protein therapies in fungi is collaborating with drug maker GlaxoSmithKline to find new small molecule drugs.
-
Synthetic Antibodies to be Designed with Organoids
A biotechnology enterprise plans to discover synthetic antibodies with 3-D printed lymph node tissue for future licensing to a pharma company.
-
Patent Board Rules for Broad Inst. in Crispr Case
A U.S. patent appeals board ruled that the Broad Institute at Harvard and MIT is the discoverer of Crispr gene editing techniques in animal cells.
-
Pharma Company Licenses Protein Delivery Hydrogel
A drug maker acquired commercialization rights to an injectable hydrogel developed at a university lab that delivers proteins to repair diseased tissue.
-
University Lab Licenses Printed Kidney Tissue Process
A start-up company is acquiring the rights to a stem cell and three-dimensional printing process to produce tissue needed by people with kidney failure.
-
Biotech Partners on Gene Editing Tech in $1.35B Deal
A biotechnology company is making its precise gene editing technology available to drug maker Pfizer for rare diseases, in a deal valued at $1.35 billion.
-
Patent Awarded for Opioid Risk System with Geographic Data
A company analyzing public health data by geography and social factors received a patent for its system identifying likely opioid addiction hot spots.
-
Regeneron Gains Cancer, Infectious Disease Immunotherapies
A biotechnology company is licensing five of its vaccines for cancer and infectious diseases to Regeneron Pharmaceuticals in a deal valued at nearly $1 billion.